{"grounding": "Leukotrienes are potent immune-regulating lipid mediators with patho-genic roles in inflammatory and allergic diseases, particularly asthma. These autacoids also contribute to low-grade inflammation, a hallmark of cardiovascular, neurodegenerative, metabolic, and tumor diseases. Biosynthesis of leukotrienes involves release and oxidative metabolism of arachidonic acid and proceeds via a set of cytosolic and integral membrane enzymes that are typically expressed by cells of the innate immune system. In activated cells, these enzymes traffic and assemble at the endoplasmic and perinuclear membrane, together comprising a biosynthetic complex. Here we describe recent advances in our molecular understanding of the protein components of the leukotriene-synthesizing enzyme machinery and also briefly touch upon the leukotriene receptors. Moreover, we discuss emerging opportunities for pharmacological intervention and development of new therapeutics.", "generated_text": "Leukotriene biosynthetic enzymes play a crucial role in the production of leukotrienes, which are potent pro-inflammatory mediators involved in various endemic diseases. The structures of these enzymes have been elucidated, revealing key binding sites for arachidonic acid and other substrates. Structure-based drug design approaches have been employed to develop novel therapeutics targeting these enzymes. Our research focuses on the design and optimization of small molecule inhibitors, with a particular emphasis on the leukotriene C4 synthase (LTC4S) and 5-lipoxygenase (5-LOX) enzymes. By modulating the activity of these enzymes, we aim to reduce inflammation and alleviate symptoms associated with diseases such as asthma and rheumatoid arthritis. The development of effective therapeutics against leukotriene biosynthetic enzymes holds significant promise for the treatment of inflammatory disorders.", "label": 1}